Innovations in Pharmaceutical Technology (IPT)
IPT provides a platform for cutting-edge ideas, concepts, and developments shaping the future of pharmaceutical R&D.
Install App?
Innovations in Pharmaceutical Technology (IPT)
www.iptonline.com
This is how the Install App dialog will look like once your App goes live.
Francis Dechoux will focus on growth opportunities across the EMEA region
Flexible containment specialist ONFAB, part of the Envair Technology group, has appointed Francis Dechoux as its new European Business Lead.
Francis will support ONFAB’s continuing growth within the pharmaceutical industry focussing on key European territories, including France, Germany, and Spain.
His role will see him take a strategic lead, helping to raise awareness and acceptance of ONFAB’s transformational flexible containment technology within the industry.
Fluent in three languages, Francis has over 30 years of experience working in business development roles with global manufacturers, mainly in the automotive industry at Mitras Automotive.
Francis said: “It’s an exciting time to be joining ONFAB. The level of growth the business is experiencing across Europe is impressive. I’m looking forward to working with customers to help them take advantage of its innovative containment solutions.”
Mark Arnold, Managing Director of ONFAB said: “With more pharmaceutical businesses using highly potent compounds, we’re seeing a huge growth in demand for flexible containment that will protect operators and prevent cross-contamination. Francis’s wealth of experience in supporting global manufacturers will be valuable as we look to onboard an increasing number of customers in Europe.”
About Envair Technology
Envair Technology was formed following the acquisition of Envair Limited by ONFAB in 2019 and Total Containment Solutions (TCS) in 2020. The group brings world class design and manufacturing expertise in clean air and containment to organisations developing or manufacturing drugs and new therapies around the world.
Working with hospitals and healthcare settings, pharmaceutical firms and R&D laboratories, the group offers a wide portfolio of products and services that protect the safety of teams handling hazardous compounds and maintain the integrity of pharmaceutical products. www.envairtechnology.com.
![[object Object]](https://cdn.magloft.com/pwa-665/article/image/15acf9e9-b0d8-4dad-bf60-64377eda682f.png?optimizer=image&width=360&aspect_ratio=3:4)
Abberior Installs State-of-the-Art STED Microscope at MBC BioLabs
GÖTTINGEN and SAN FRANCISCO, March 24, 2023 – Life Science Newswire – Abberior, a leading provider of cutting-edge imaging technologies, announced today that they have placed a super-resolution STED microscope at MBC BioLabs, the leading San Francisco Bay Area biotech incubator network. The installation is part of Abberior's efforts to support biotech entrepreneurs in launching and growing innovative life science companies.
![[object Object]](https://cdn.magloft.com/pwa-665/article/image/f372f74f-b4fe-4303-a51f-71f6a55534ea.png?optimizer=image&width=360&aspect_ratio=3:4)
Vantage Nutrition LLC acquires ComboCap Inc.
27 March 2023 -- Vantage Nutrition, an ACG group company announces full shareholding ownership of ComboCap Inc (USA) and BioCap (South Africa).
![[object Object]](https://cdn.magloft.com/pwa-665/article/image/2f964cf0-b266-45fc-b879-9ceae5203751.png?optimizer=image&width=360&aspect_ratio=3:4)
AbCellera and RQ Bio Partner to Accelerate the Advancement of New Therapies for Infectious Disease
VANCOUVER, British Columbia & LONDON, March 22, 2023 – AbCellera (Nasdaq: ABCL) and RQ Bio announced today that they have entered into a strategic collaboration to identify optimal clinical candidates for up to three infectious disease targets selected by RQ Bio, including influenza and cytomegalovirus (CMV).
![[object Object]](https://cdn.magloft.com/pwa-665/article/image/bb0009cf-93f4-44e7-abbe-84625f8e7126.png?optimizer=image&width=360&aspect_ratio=3:4)
Invitae and Deerfield Management Partner to Create Novel Therapeutics for Rare Diseases
SAN FRANCISCO, March 22, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, and Deerfield Management Company, a healthcare investment firm, today announced a partnership to advance genetics-based drug discovery and development in rare disease. The partnership will leverage genetics and clinical data from millions of patients and Deerfield's broad drug discovery and development expertise.
![[object Object]](https://cdn.magloft.com/pwa-665/article/image/1ba3a206-0a8c-4d23-b804-920597d7e935.png?optimizer=image&width=360&aspect_ratio=3:4)
Citeline Finalist CluePoints Show Advanced AI Capabilities
King of Prussia, PA – March 23rd, 2023: CluePoints, the premier provider of Risk-Based Study Execution (RBx) and Risk-Based Quality Management Software for clinical trials, has announced it has been shortlisted for the 2023 Citeline Awards in the Best Use of Artificial Intelligence in Clinical Trials category.
1
Human-Centred Design: From Inception to Integration
IPT sat down with Dr Chris Vincent at PDD, to understand more about the digital innovations that are leading design and whether technologies like Extended Reality (XR) can be beneficial to the process
2
The Importance of Temperature Control in Pharmaceutical Analysis
As technology within the analysis sphere continues to evolve, temperature control is becoming increasingly important for drug discovery and research
3
Providing Support Throughout the Patient Journey
Concierge services are critical to helping patients navigate technology and other logistics in a decentralised clinical trial. How best can they be implemented?
